OncoLink Cancer Treatment and Resources
Link to OncoLink

Conventionally Fractionated Stereotactic Radiotherapy for Vestibular Schwannoma: Long-Term Outcome and Cranial Nerve Function

Diana Stripp, MD
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 8 de noviembre del 2001

Presenter: Chan, A
Presenter's Affiliation: Massachusetts Gerneral Hospital, Boston, MA
Type of Session: Scientific

Background

  • Vestibular schwannoma/acoutic neuroma comprises 8% of all primary brain tumors.
  • It?s location ? closely associated with brain stem and cranial nerve, creates great challenge for treatment.
  • Surgical outcome has shown good results with tumor < 2cm. However, for tumor >2cm, cranial nerve damage could be permenant.
  • 1945, 1st fractionated radiotherapy (RT) was done at UCSF. 1987, 1st large study on fractionated RT.

    Materials and Methods

  • 48 patients (1993-2000) with vestibular schwannoma were treated with linac accelerator-based stereotactic radiotherapy at the Massachusetts General Hospital or Brigham and Women?s Hospital.
  • 6 patients with neurofibromatosis type II, and 5 patients had intracanicular tumors only.
  • 39 patients were treated with primary radiotherapy and 9 patients were treated after primary surgical resection for persistent (n = 1) or recurrent (n = 8) disease.
  • Six patients had pre-existing facial paresis at the time of radiation (House-Brackmann class 2 in 1, class 4 in 1, class 5 in 3, and class 6 in 1).
  • The median tumor volume was 3.1 cc (range: 0.17 cc - 21.07 cc). The median dose was 54 Gy in 1.8 Gy per fraction prescribed to 95% of the isodose.
  • Computerized tomography/magnetic resonance images were used for target definition. Conformal treatment plans were generated using one isocenter and three to six non-coplanar arcs. Follow-up duration ranged from 12 to 77 months.

    Results

  • The overall local control rate (stabilization or regression of tumor) was 94%.
  • Post-radiation surgical intervention was performed in 3 patients (6%); two underwent microsurgical resection at 39 and 44 months for progressive enlargement of tumors, and one underwent shunt placement for persistent hydrocephalus and progressive disease at 6 months.
  • The rate of hearing preservation (maintenance of the pre-treatment Gardner-Robertson hearing function class or no subjective decline of hearing) was 83%.
  • All patients with pre-treatment useful hearing (Gardner-Robertson class 1 - 2) maintained useful hearing after radiation.
  • Pre-treatment normal facial and trigeminal nerve function was preserved in all cases.
  • One patient with an intracanicular tumor and a pre-treatment House-Brackmann class 2 facial dysfunction developed permanent class 5 facial weakness during the first week of radiation. Mild trigeminal toxicity was observed in one patient at 18 months after radiation.
  • There were no other complications or second cancer

    Author's Conclusions
    Stereotactic radiotherapy using a conventionally fractionated schedule results in local control rate comparable with that reported for gamma knife radiosurgery and microsurgery resection, but with a high rate of hearing preservation and a very low rate of trigeminal and facial neuropathy

    Clinical/Scientific Implications

  • Improved rate of hearing preservation and low rate of trigeminal and facial neuropathy provides a very attractive therapeutic scheme for treatment of vestibular schwannoma, if feasible with individual clinics.
  • Long term follow up is needed to evaluation late recurrence

  • OncoLink I wish u knew...

    Dr. Mao talks about complementary and alternative medicine and the importance of being open about their use with cancer caregivers. Read more.

    Cancer Types
    Bone Cancer
    Brain Tumors
    Breast Cancer
    Carcinoid Tumors
    Endocrine System Cancers
    Gastrointestinal Cancers
    Gynecologic Cancers
    Head and Neck Cancers
    Leukemia
    Lung Cancers
    Lymphomas
    Myelomas
    Pediatric Cancers
    Penile Cancer
    Prostate Cancer
    Sarcomas
    Skin Cancers
    Testicular Cancer
    Thyroid Cancer
    Urinary Tract Cancers
    OncoLink Vet

    Cancer Treatment
    Biologic Therapy
    Bone Marrow Transplants
    Chemotherapy

    Clinical Trials
    Complementary Medicine
    Gene Therapy
    General Treatment Concerns
    Hormone Therapy
    PDT Center
    Proton Therapy
    Radiation Oncology
    Surgical Oncology
    Targeted Therapies
    Vaccine Therapies

    Cancer Support
    Caregivers
    Hospice Care and Bereavement
    Nutrition and Cancer
    Sexuality & Fertility
    Side Effects
    Support
    Survivorship
    Exercise and Cancer

    Cancer Resources
    Cancer News
    OncoLink University
    Nurses' Notes
    Conferences
    Newly Diagnosed Patients
    Causes and Prevention
    Legal and Financial Information for Patients
    LGBT Resources
    NCI Resources
    Global Resources
    Cancer Resource List
    Resources for Young Adults

    OncoLink Media Library
    OncoLink TV
    Book, Music and Video Reviews


    Ask the Experts
    Brown Bag Chat
    Tracy's Corner

    About OncoLink
    About OncoLink
    Giving to OncoLink
    Contact Information
    Usage Policy
    Editorial Board
    How to Partner with OncoLink
    Link to OncoLink
    Mission Statement

    OncoLink Cancer Resources RSS What's New RSS